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Oxybutynin (OXY) used in combination with clean inter-
mittent catheterisation (CIC), has been the first-line med-
ication for treatment of neurogenic bladder dysfunction
over the past two decades. The efficacy of oral OXY in
treatment of neurogenic bladder has been demonstrated
in several studies. OXY has been shown to increase the
maximum bladder capacity, decrease the maximum
detrusor pressure with filling, and in combination with
CIC, help prevent upper urinary tract deterioration. Until
recently, OXY was only available in immediate-release
tablets and syrup, both usually requiring dosing two or
three times daily, with increased opportunity for missed
doses. Intravesical OXY has been used with refractory
patients or individuals who could not tolerate the sys-
temic anti-cholinergic side effects, and has been shown to
be effective. However, other problems including non-
compliance, difficulty with instillation, leakage of medi-
cation, etc. have limited its general appeal. With the
advent of a long-acting OXY preparation (Ditropan XL),
OXY could be given orally just once daily with reduced
side-effects for many patients. Even more recently, a
transdermal OXY (Oxytrol) delivery system has been
tested, FDA-approved and marketed in the United States.
A randomised, double-blind, study of transdermal OXY
versus immediate-release oral OXY in patients with urge
incontinence showed comparable efficacy with lower side
effects (Davila 2001).
In another study, it was shown that transdermal OXY as a
3.9 mg/day patch (Oxytrol) provides a steady-state level
of oxybutynin that is favourable compared to the 10 mg
Ditropan XL, with even lower levels of the metabolite, N-
desthyloxy-butynin, the compound felt to be most
responsible for annoying anti-cholinergic side effects
(Appell 2003). To date, there is no published study evalu-
ating the use of transdermal OXY in the treatment of neu-
rogenic bladder dysfunction or in spina bifida.
In our Spina Bifida Center, we have begun using the oxy-
butynin transdermal delivery system (OTDS) in select
patients: those with significant side effects and those who
had problems with compliance on oral OXY preparations.
To date, we have used OTDS in 8 individuals with spina
bifida ranging in age from 6 to 41 years (average 19 years).
None of the individuals have discontinued the OTDS. All
have shown a decrease in side effects compared to oral
anti-cholinergics, with similar or improved urinary conti-
nence.
Transdermal oxybutynin shows considerable promise in
the treatment of neurogenic bladder dysfunction. Further
studies of dosing and efficacy are needed, especially in
children.
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